Share chart Biohaven Pharmaceutical Holding Company Ltd.
Extended chart
Simple chart
About Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceutical Holding Company Ltd., биофармацевтическая компания на клинической стадии, разрабатывает продукты-кандидаты на поздних стадиях, нацеленные на неврологические заболевания и редкие расстройства в Соединенных Штатах. Его продукты на клинической стадии включают Римегепант, продукт, который прошел III фазу испытаний для лечения острых состояний и профилактики мигрени; Вазегепант, завершивший испытание фазы 2> F3 по неотложному лечению и профилактике мигрени; и Трорилузол, завершивший фазу рандомизации II \ u002FIII и продолжающийся расширенное исследование атаксии. more details| IPO date | 2022-09-23 |
|---|---|
| ISIN | VGG111961055 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | http://www.biohavenpharma.com |
| Цена ао | 29.87 |
| Change price per day: | 0% (29.87) |
|---|---|
| Change price per week: | +3.9% (28.75) |
| Change price per month: | -15.93% (35.53) |
| Change price per 3 month: | -16.45% (35.75) |
| Change price per half year: | -41.64% (51.18) |
| Change price per year: | -46.94% (56.29) |
| Change price per 3 year: | 0% (29.87) |
| Change price per 5 year: | 0% (29.87) |
| Change price per 10 year: | 0% (29.87) |
| Change price per year to date: | -20.03% (37.35) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Stifel Financial Corporation | 6225811 | 7.63 |
| Janus Henderson Group PLC | 5901343 | 7.23 |
| Blackrock Inc. | 5762738 | 7.06 |
| Suvretta Capital Management, LLC | 4572836 | 5.6 |
| State Street Corporation | 3870839 | 4.74 |
| Price (T.Rowe) Associates Inc | 3134323 | 3.84 |
| RP Management, LLC | 2936507 | 3.6 |
| Point72 Asset Management, L.P. | 2483567 | 3.04 |
| Adage Capital Partners GP L.L.C. | 2020644 | 2.48 |
| FMR, LLC | 1928992 | 2.36 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| PSYK ETF | 7.04 | 0 | |
| iShares Neuroscience and Healthcare ETF | 4.14142 | 19.72 | 0.03 |
iShares Russell 2000 Growth ETF
|
0.22426 | 38.04 | 0.6026 |
| iShares Morningstar Small-Cap Growth ETF | 0.13211 | 33.63 | 0.72598 |
| iShares Morningstar Small-Cap Growth ETF | 0.13211 | 587.89 | 0.72598 |
| iShares ESG Aware MSCI USA Small-Cap ETF | 0.08795 | 18.09 | 1.49366 |
| iShares Morningstar Small-Cap ETF | 0.06651 | 30.1 | 1.60498 |
| iShares Morningstar Small-Cap ETF | 0.06651 | 391.25 | 1.60498 |
| iShares Russell 3000 ETF | 0.00529 | 24.83 | 1.43482 |
| 1.32 | 127.06 | 0.91 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Ms. Kimberly Gentile | Senior Vice President of Clinical Operations | 858.65k | 1966 (59 years) |
| Mr. Clifford Bechtold M.S. | President, GM of Biohaven Ireland & Chief Compliance Officer | N/A | |
| Mr. George C. Clark | VP & Chief Accounting Officer | N/A | 1984 (41 year) |
| Dr. Vladimir Coric M.D. | Chairman & CEO | 1.96M | 1971 (54 years) |
| Mr. Matthew Buten | Chief Financial Officer | 1.05M | 1961 (64 years) |
| Dr. Bruce D. Car DACVP, Ph.D. | Chief Scientific Officer | 883.03k | 1962 (63 years) |
| Ms. Jennifer Porcelli | Vice President of Investor Relations | N/A | |
| Mr. John Tilton | Chief Commercial Officer of Rare Diseases | N/A | 1968 (57 years) |
| Ms. Deb Young | Director of Regulatory Affairs & Operations | N/A | |
| Mr. Warren Volles J.D. | General Counsel & Chief Legal Officer | N/A |
Address: United States, New Haven, CT , 215 Church Street - open in Google maps, open in Yandex maps
Website: http://www.biohavenpharma.com
Website: http://www.biohavenpharma.com
